Get the Stockscreener App
2.555
3.03%
-0.085
2 Seventy Bio Inc stock is traded at $2.555, with a volume of 110.46K.
It is down -3.03% in the last 24 hours and down -1.16% over the past month.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$2.64
Open:
$2.57
24h Volume:
110.46K
Relative Volume:
0.35
Market Cap:
$133.61M
Revenue:
$44.12M
Net Income/Loss:
$-156.25M
P/E Ratio:
-0.8322
EPS:
-3.07
Net Cash Flow:
$-154.61M
1W Performance:
-2.66%
1M Performance:
-1.16%
6M Performance:
-42.21%
1Y Performance:
-54.61%
1-Day Range:
$2.515
$2.665
1-Week Range:
$2.398
$2.69
52-Week Range:
$2.29
$5.99
2 Seventy Bio Inc Stock (TSVT) Company Profile
Name
2 Seventy Bio Inc
Sector
Industry
Phone
339-499-9300
Address
60 BINNEY STREET, CAMBRIDGE
Compare TSVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
2.56 | 133.61M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.36 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.30 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
632.13 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.03 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.81 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Downgrade | Goldman | Neutral → Sell |
| Jan-31-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-31-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-30-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| May-02-22 | Initiated | Goldman | Buy |
| Feb-10-22 | Initiated | SVB Leerink | Outperform |
| Jan-06-22 | Initiated | Cowen | Outperform |
| Nov-09-21 | Initiated | Canaccord Genuity | Buy |
| Nov-08-21 | Initiated | Morgan Stanley | Overweight |
| Nov-08-21 | Initiated | Wedbush | Outperform |
View All
2 Seventy Bio Inc Stock (TSVT) Latest News
Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewswire
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference - Business Wire
2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Exchange Traded Concepts LLC - Defense World
2 Seventy Bio Inc Stock (TSVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2 Seventy Bio Inc Stock (TSVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
| Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
| Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
| Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
| Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
| Eatwell Victoria | Chief Financial Officer |
Jan 06 '25 |
Sale |
2.78 |
97 |
270 |
338,979 |
| Baird William D III | President and CEO |
Jan 03 '25 |
Sale |
2.94 |
31,718 |
93,121 |
862,889 |
| Baird William D III | President and CEO |
Jan 06 '25 |
Sale |
2.78 |
763 |
2,120 |
862,126 |
| Snow Jessica | See Remarks |
Dec 13 '24 |
Sale |
3.23 |
2,287 |
7,393 |
153,479 |
4.26%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):